Comment by AcornAl on 04/02/2025 at 01:50 UTC

6 upvotes, 0 direct replies (showing 0)

View submission: Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

View parent comment

Results for pemivibart are fairly positive, so one can assume VYD2311 should be better, but probably premature to consider this as an alternative for vaccinations from a small trial with 40 people.

In Australia and the UK, we don't even recommend vaccinations to non-risk groups anymore due to the high cost, so it would be hard to see them recommending something else with a similar $/QALY. Possibly a great alternative for those that are immunosuppressed and potentially a treatment option?

• As an aside, I wonder what companies design drugs to be a non-superior alternative to existing products. You have to love shareholder media releases. ;)*

Replies

There's nothing here!